Loading
Life sciences · Review
Taiwanese Journal of Obstetrics and Gynecology · October 29, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Review.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Gestational Diabetes Mellitus (GDM) is a prevalent metabolic disorder affecting approximately 14% of pregnancies worldwide, with increasing incidence linked to rising obesity rates among women of reproductive age. GDM significantly impacts placental structure and function, leading to adverse maternal and fetal outcomes. Inositols, particularly myo-inositol (myo-Ins), play important roles in cellular signaling, glucose homeostasis, and insulin sensitivity, making them relevant to GDM pathophysiology. Myo-Ins, the most abundant inositol stereoisomer, is obtained through dietary intake and biosynthesis, with its metabolism intricately linked to insulin signaling. This review explores the role of myo-Ins in placental metabolism and its potential implications for GDM management. We discuss the potential mechanisms by which myo-Ins might influence glucose homeostasis, oxidative stress, inflammation, and lipid metabolism in the placenta, highlighting potential protective effects against GDM-induced placental dysfunction. Some clinical evidence suggests that myo-Ins supplementation may reduce the risk of GDM, improve insulin sensitivity, and mitigate adverse pregnancy outcomes. However, the timing, dosage, and specific placental effects require further investigation to optimize therapeutic efficacy. This review underscores the potential of myo-Ins as an adjunctive therapy for GDM, emphasizing the need for further research to elucidate mechanisms of action and long-term benefits for maternal and fetal health.